Sodium glycerophosphate
As of the edition of 20 October 2026, Sodium glycerophosphate is a drug: marketed, first approved in 1999 (FR).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2014
- Kind
- Unknown
- Brand name
- Kabiven In Plastic Container
- First approved
- 8 November 1999 (FR)
- Approvals on record
- 13 in 3 regions
- Holder of the most recent approval
- Fresenius Kabi; 3 holders in all
- Registered trials
- 4, 0 stopped early
- Disease areas
- Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 1 | 1 | 0 |
| Phase 1 | 2 | 2 | 0 | 0 |
| All trials | 4 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Baxter Healthcare | Applicant and Lead sponsor of trials | 2010 to now |
| Fresenius Kabi | Applicant | 2026 to now |